Another randomized, double-blind, placebo-controlled phase 2 trial in patients with T2D and obesity presented significant improved HDL-C and TG, fibrosis biomarkers, as well as increased adiponectin levels after administration of s.c. pegbelfermin for 12 weeks [48]. The gene discussed is ADIPOQ; the disease is obesity due to melanocortin 4 receptor deficiency.